IBRX Clinical trials

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Published August 13, 2025 at 12:30 PM

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. QUILT-106 (NCT06334991) is a first-in-human trial evaluating the safety and preliminary efficac

Related Questions

How will the early complete response data from QUILT‑106 affect ImmunityBio's short‑term stock momentum? What is the expected timeline for further data read‑outs or expansion cohorts from the Phase I trial? Will the chemotherapy‑free approach potentially expand the addressable patient pool and drive higher market adoption? What are the projected revenue implications if the therapy progresses to later‑stage trials and eventual commercialization? How might this news impact analyst coverage and consensus estimates for ImmunityBio? Are there any regulatory or manufacturing hurdles that could delay the development timeline for the CD19 CAR‑NK product? What is the competitive landscape for CAR‑NK therapies targeting CD19 and how might ImmunityBio's first‑in‑class status affect its market positioning? Could this early success trigger partnership or licensing interest from larger pharmaceutical companies? How sensitive is ImmunityBio's valuation to future clinical trial outcomes and potential dilution from upcoming financing rounds? How does the efficacy of ImmunityBio's CD19 CAR‑NK platform compare to existing CD19 CAR‑T therapies in terms of response rates and safety profile?